

# Vivianne Presta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3542508/publications.pdf>

Version: 2024-02-01

407  
papers

21,944  
citations

53794

45  
h-index

10734

138  
g-index

417  
all docs

417  
docs citations

417  
times ranked

25324  
citing authors

#	ARTICLE	IF	CITATIONS
1	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018, 39, 3021-3104.	2.2	6,826
2	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2013, 34, 2159-2219.	2.2	5,681
3	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , 2006, 28, 88-136.	2.2	1,144
4	Age and Multimorbidity Predict Death Among COVID-19 Patients. <i>Hypertension</i> , 2020, 76, 366-372.	2.7	330
5	Natriuretic peptides in cardiovascular diseases: current use and perspectives. <i>European Heart Journal</i> , 2014, 35, 419-425.	2.2	221
6	The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. <i>Clinical Science</i> , 2015, 130, 57-77.	4.3	208
7	Trehalose-Induced Activation of Autophagy Improves Cardiac Remodeling After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1999-2010.	2.8	195
8	Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years. <i>Hypertension</i> , 2020, 75, 302-308.	2.7	177
9	Current Situation of Medication Adherence in Hypertension. <i>Frontiers in Pharmacology</i> , 2017, 8, 100.	3.5	173
10	An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy. <i>Cardiovascular Research</i> , 2017, 113, 378-388.	3.8	164
11	Adverse Epigenetic Signatures by Histone Methyltransferase Set7 Contribute to Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 150-158.	5.1	141
12	Impact of Glycemic Variability on Chromatin Remodeling, Oxidative Stress, and Endothelial Dysfunction in Patients With Type 2 Diabetes and With Target HbA1c Levels. <i>Diabetes</i> , 2017, 66, 2472-2482.	0.6	139
13	A New Electrocardiographic Marker of Sudden Death in Brugada Syndrome. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1427-1440.	2.8	133
14	Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. <i>Clinical Science</i> , 2009, 116, 467-477.	4.3	122
15	Blood pressure control in Italy: results of recent surveys on hypertension. <i>Journal of Hypertension</i> , 2007, 25, 1491-1498.	0.5	117
16	mTORC2 Regulates Cardiac Response to Stress by Inhibiting MST1. <i>Cell Reports</i> , 2015, 11, 125-136.	6.4	110
17	Development of heart failure in recent hypertension trials. <i>Journal of Hypertension</i> , 2008, 26, 1477-1486.	0.5	105
18	Natriuretic peptides and cardio-renal disease. <i>International Journal of Cardiology</i> , 2014, 176, 630-639.	1.7	102

#	ARTICLE	IF	CITATIONS
19	Pathogenesis of Target Organ Damage in Hypertension: Role of Mitochondrial Oxidative Stress. <i>International Journal of Molecular Sciences</i> , 2015, 16, 823-839.	4.1	95
20	Effect of resveratrol on blood pressure: A systematic review and meta-analysis of randomized, controlled, clinical trials. <i>Critical Reviews in Food Science and Nutrition</i> , 2019, 59, 1605-1618.	10.3	94
21	New Insights into the Role of Mitochondrial Dynamics and Autophagy during Oxidative Stress and Aging in the Heart. <i>Oxidative Medicine and Cellular Longevity</i> , 2014, 2014, 1-13.	4.0	92
22	Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications. <i>Frontiers in Medicine</i> , 2021, 8, 798958.	2.6	88
23	Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation. <i>Journal of Hypertension</i> , 2012, 30, 1056-1064.	0.5	86
24	Efficacy and Tolerability of Olmesartan Medoxomil Combined with Amlodipine in Patients with Moderate to Severe Hypertension after Amlodipine Monotherapy. <i>Clinical Drug Investigation</i> , 2009, 29, 11-25.	2.2	83
25	Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers and Diabetes: A Meta-Analysis of Placebo-Controlled Clinical Trials. <i>American Journal of Hypertension</i> , 2011, 24, 582-590.	2.0	78
26	Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. <i>Journal of Hypertension</i> , 2007, 25, 2317-2324.	0.5	77
27	Targeting prolyl-isomerase Pin1 prevents mitochondrial oxidative stress and vascular dysfunction: insights in patients with diabetes. <i>European Heart Journal</i> , 2015, 36, 817-828.	2.2	75
28	VEGFR (Vascular Endothelial Growth Factor Receptor) Inhibition Induces Cardiovascular Damage via Redox-Sensitive Processes. <i>Hypertension</i> , 2018, 71, 638-647.	2.7	73
29	Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: The URRAH (Uric Acid Right for Heart Health) study. <i>Journal of Hypertension</i> , 2020, 38, 412-419.	0.5	70
30	Obesity-induced activation of JunD promotes myocardial lipid accumulation and metabolic cardiomyopathy. <i>European Heart Journal</i> , 2019, 40, 997-1008.	2.2	69
31	Early Impairment of Renal Hemodynamic Reserve in Patients With Asymptomatic Heart Failure Is Restored by Angiotensin II Antagonism. <i>Circulation</i> , 1998, 98, 2849-2854.	1.6	65
32	The challenge of polypharmacy in cardiovascular medicine. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 9-17.	1.9	62
33	Hypertension, a Moving Target in COVID-19. <i>Circulation Research</i> , 2021, 128, 1062-1079.	4.5	61
34	Personalized medicine—a modern approach for the diagnosis and management of hypertension. <i>Clinical Science</i> , 2017, 131, 2671-2685.	4.3	59
35	2012 Consensus Document of the Italian Society of Hypertension (SIIA): Strategies to Improve Blood Pressure Control in Italy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2013, 20, 45-52.	2.2	57
36	Is early and fast blood pressure control important in hypertension management?. <i>International Journal of Cardiology</i> , 2018, 254, 328-332.	1.7	56

#	ARTICLE	IF	CITATIONS
37	Why in 2016 are patients with hypertension not 100% controlled? A call to action. <i>Journal of Hypertension</i> , 2016, 34, 1480-1488.	0.5	52
38	Gender differences in predictors of intensive care units admission among COVID-19 patients: The results of the SARS-RAS study of the Italian Society of Hypertension. <i>PLoS ONE</i> , 2020, 15, e0237297.	2.5	51
39	NOX4 regulates autophagy during energy deprivation. <i>Autophagy</i> , 2014, 10, 699-701.	9.1	50
40	Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy. <i>Heart</i> , 2016, 102, 602-609.	2.9	50
41	Efficacy and Safety of Triple Antihypertensive Therapy with the Olmesartan/Amlodipine/Hydrochlorothiazide Combination. <i>Clinical Drug Investigation</i> , 2012, 32, 649-664.	2.2	49
42	Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study. <i>Journal of Hypertension</i> , 2021, 39, 62-69.	0.5	49
43	Beyond hypertension toward guidelines for cardiovascular risk reduction. <i>American Journal of Hypertension</i> , 2004, 17, 1068-1074.	2.0	48
44	Arterial hypertension in cancer: The elephant in the room. <i>International Journal of Cardiology</i> , 2019, 281, 133-139.	1.7	48
45	Hyperglycaemia-induced epigenetic changes drive persistent cardiac dysfunction via the adaptor p66Shc. <i>International Journal of Cardiology</i> , 2018, 268, 179-186.	1.7	47
46	Molecular Implications of Natriuretic Peptides in the Protection from Hypertension and Target Organ Damage Development. <i>International Journal of Molecular Sciences</i> , 2019, 20, 798.	4.1	47
47	Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. <i>Journal of Hypertension</i> , 2005, 23, 2113-2118.	0.5	46
48	Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study. <i>Journal of Hypertension</i> , 2021, 39, 333-340.	0.5	46
49	Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy. <i>Journal of Cardiovascular Electrophysiology</i> , 2015, 26, 893-899.	1.7	45
50	Trends in Prevalence, Awareness, Treatment, and Control of Blood Pressure Recorded From 2004 to 2014 During World Hypertension Day in Italy. <i>Journal of Clinical Hypertension</i> , 2016, 18, 551-556.	2.0	45
51	Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity. <i>European Heart Journal</i> , 2019, 40, 383-391.	2.2	45
52	Efficacy and Safety of a Stepped-Care Regimen Using Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide in Patients with Moderate-to-Severe Hypertension. <i>Clinical Drug Investigation</i> , 2009, 29, 381-391.	2.2	44
53	Is it time to measure microalbuminuria in hypertension?. <i>Journal of Hypertension</i> , 2003, 21, 1213-1220.	0.5	43
54	Hypertension in Young People: Epidemiology, Diagnostic Assessment and Therapeutic Approach. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 381-388.	2.2	43

#	ARTICLE	IF	CITATIONS
55	Ndufc2 Gene Inhibition Is Associated With Mitochondrial Dysfunction and Increased Stroke Susceptibility in an Animal Model of Complex Human Disease. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	43
56	100% Fruit juice intake and cardiovascular risk: a systematic review and meta-analysis of prospective and randomised controlled studies. <i>European Journal of Nutrition</i> , 2021, 60, 2449-2467.	3.9	43
57	Incidence and determinants of high-sensitivity troponin and natriuretic peptides elevation at admission in hospitalized COVID-19 pneumonia patients. <i>Internal and Emergency Medicine</i> , 2020, 15, 1467-1476.	2.0	42
58	Epigenetics and cardiovascular regenerative medicine in the elderly. <i>International Journal of Cardiology</i> , 2018, 250, 207-214.	1.7	41
59	Chronic kidney disease in hypertension under specialist care: the I-DEMAND study. <i>Journal of Hypertension</i> , 2010, 28, 156-162.	0.5	40
60	Calcium Channel Blockers and Hypertension. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2015, 20, 121-130.	2.0	40
61	Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy. <i>Atherosclerosis</i> , 2019, 285, 40-48.	0.8	39
62	Native T1 and T2 provide distinctive signatures in hypertrophic cardiac conditions – Comparison of uremic, hypertensive and hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2020, 306, 102-108.	1.7	39
63	Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 12-18.	3.0	38
64	Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 105-108.	2.2	37
65	Mitochondrial Dysfunction Contributes to Hypertensive Target Organ Damage: Lessons from an Animal Model of Human Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-10.	4.0	36
66	Prevalence and clinical outcomes of white-coat and masked hypertension: Analysis of a large ambulatory blood pressure database. <i>Journal of Clinical Hypertension</i> , 2018, 20, 297-305.	2.0	36
67	Natriuretic Peptides in the Cardiovascular System: Multifaceted Roles in Physiology, Pathology and Therapeutics. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3991.	4.1	36
68	Fewer Mega-Trials and More Clinically Oriented Studies in Hypertension Research? The Case of Blocking the Renin-Angiotensin-Aldosterone System. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, S36-S43.	6.1	35
69	Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. <i>Journal of Nephrology</i> , 2022, 35, 211-221.	2.0	34
70	Twisting arms to angiotensin receptor blockers/antagonists: the turn of cancer. <i>European Heart Journal</i> , 2011, 32, 19-22.	2.2	33
71	2007 ESH/ESC Guidelines for the management of hypertension, from theory to practice: global cardiovascular risk concept. <i>Journal of Hypertension</i> , 2009, 27, S3-S11.	0.5	31
72	Prediction of Long-Term Survival in Chronic Heart Failure by Multiple Biomarker Assessment: A 15-Year Prospective Follow-Up Study. <i>Clinical Cardiology</i> , 2010, 33, 700-707.	1.8	31

#	ARTICLE	IF	CITATIONS
73	Antihypertensive Therapy in Diabetes: The Legacy Effect and RAAS Blockade. <i>Current Hypertension Reports</i> , 2011, 13, 318-324.	3.5	31
74	The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk. <i>Clinical Research in Cardiology</i> , 2021, 110, 1073-1082.	3.3	31
75	Role of oxidative stress in the process of vascular remodeling following coronary revascularization. <i>International Journal of Cardiology</i> , 2018, 268, 27-33.	1.7	30
76	Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials. <i>Journal of Hypertension</i> , 2009, 27, 941-946.	0.5	29
77	Lipoprotein (a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease. <i>Atherosclerosis</i> , 2016, 246, 214-220.	0.8	29
78	Reduced brain UCP2 expression mediated by microRNA-503 contributes to increased stroke susceptibility in the high-salt fed stroke-prone spontaneously hypertensive rat. <i>Cell Death and Disease</i> , 2017, 8, e2891-e2891.	6.3	29
79	Pulmonary hypertension and clinical correlates in hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2017, 248, 326-332.	1.7	28
80	In vitro characterization of mitochondrial function and structure in rat and human cells with a deficiency of the NADH: ubiquinone oxidoreductase Ndufc2 subunit. <i>Human Molecular Genetics</i> , 2017, 26, 4541-4555.	2.9	28
81	Might renin-angiotensin system blockers play a role in the COVID-19 pandemic?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 248-251.	3.0	28
82	Awareness of major cardiovascular risk factors and its relationship with markers of vascular aging: Data from the Brisighella Heart Study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 907-914.	2.6	27
83	Differential modulation of AMPK/PPAR $\alpha$ /UCP2 axis in relation to hypertension and aging in the brain, kidneys and heart of two closely related spontaneously hypertensive rat strains. <i>Oncotarget</i> , 2015, 6, 18800-18818.	1.8	27
84	Dickkopf-3 Upregulates VEGF in Cultured Human Endothelial Cells by Activating Activin Receptor-Like Kinase 1 (ALK1) Pathway. <i>Frontiers in Pharmacology</i> , 2017, 8, 111.	3.5	26
85	Home Blood Pressure and Telemedicine: A Modern Approach for Managing Hypertension During and After COVID-19 Pandemic. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 1-14.	2.2	26
86	Association of renal damage with cardiovascular diseases is independent of individual cardiovascular risk profile in hypertension: data from the Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. <i>Journal of Hypertension</i> , 2010, 28, 251-258.	0.5	25
87	Effects of a Long-Term Treatment With Aliskiren or Ramipril on Structural Alterations of Subcutaneous Small-Resistance Arteries of Diabetic Hypertensive Patients. <i>Hypertension</i> , 2014, 64, 717-724.	2.7	25
88	ARB-Based Single-Pill Platform to Guide a Practical Therapeutic Approach to Hypertensive Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2014, 21, 137-47.	2.2	25
89	ARNi: A Novel Approach to Counteract Cardiovascular Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2092.	4.1	25
90	Blood Pressure Levels at the Time of Percutaneous Coronary Revascularization and Risk of Coronary In-Stent Restenosis. <i>American Journal of Hypertension</i> , 2016, 29, 509-518.	2.0	23

#	ARTICLE	IF	CITATIONS
91	Admission heart rate and in-hospital course of patients with Takotsubo syndrome. <i>International Journal of Cardiology</i> , 2018, 273, 15-21.	1.7	23
92	Natriuretic peptides in heart failure: Current achievements and future perspectives. <i>International Journal of Cardiology</i> , 2019, 281, 186-189.	1.7	23
93	Dual RAAS suppression: recent developments and implications in light of the ALTITUDE study. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012, 13, 409-412.	1.7	22
94	Highlights of ESC/ESH 2018 Guidelines on the Management of Hypertension: What Every Doctor Should Know. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 1-8.	2.2	22
95	Challenging hypertension: how to diagnose and treat resistant hypertension in daily clinical practice. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 811-820.	1.5	21
96	Effects of dual angiotensin type 1 receptor/nepriylsin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat. <i>Journal of Hypertension</i> , 2018, 36, 1902-1914.	0.5	21
97	Clinical Characteristics and Outcomes of Patients with COVID-19 Infection: The Results of the SARS-RAS Study of the Italian Society of Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 5-11.	2.2	21
98	The importance of endothelial dysfunction in resistance artery remodelling and cardiovascular risk. <i>Cardiovascular Research</i> , 2019, 116, 429-437.	3.8	20
99	Incidence, determinants and prognostic relevance of dyspnea at admission in patients with Takotsubo syndrome: results from the international multicenter GEIST registry. <i>Scientific Reports</i> , 2020, 10, 13603.	3.3	20
100	Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study. <i>Journal of Human Hypertension</i> , 2022, 36, 976-982.	2.2	20
101	Determinants of healing among patients with coronavirus disease 2019: the results of the SARS-RAS study of the Italian Society of Hypertension. <i>Journal of Hypertension</i> , 2021, 39, 376-380.	0.5	20
102	An interplay between UCP2 and ROS protects cells from high-salt-induced injury through autophagy stimulation. <i>Cell Death and Disease</i> , 2021, 12, 919.	6.3	20
103	Renal Artery Denervation for Treating Resistant Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2012, 19, 237-244.	2.2	19
104	A guide for easy- and difficult-to-treat hypertension. <i>International Journal of Cardiology</i> , 2014, 172, 17-22.	1.7	19
105	A Next-Generation Sequencing Approach to Identify Gene Mutations in Early- and Late-Onset Hypertrophic Cardiomyopathy Patients of an Italian Cohort. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1239.	4.1	19
106	Attenuated IGF-1 predicts all-cause and cardiovascular mortality in a Black population: A five-year prospective study. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1690-1699.	1.8	19
107	Has the SPRINT trial introduced a new blood-pressure goal in hypertension?. <i>Nature Reviews Cardiology</i> , 2017, 14, 560-565.	13.7	19
108	Nocturnal blood pressure patterns and cardiovascular outcomes in patients with masked hypertension. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1238-1246.	2.0	19

#	ARTICLE	IF	CITATIONS
109	Clinical and prognostic impact of chronotropic incompetence in patients with hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2018, 271, 125-131.	1.7	19
110	The reduction of NDUFC2 expression is associated with mitochondrial impairment in circulating mononuclear cells of patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2019, 286, 127-133.	1.7	19
111	Mas Receptor Activation Contributes to the Improvement of Nitric Oxide Bioavailability and Vascular Remodeling During Chronic AT1R (Angiotensin Type-1 Receptor) Blockade in Experimental Hypertension. <i>Hypertension</i> , 2020, 76, 1753-1761.	2.7	19
112	Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence. <i>International Journal of Cardiology</i> , 2021, 327, 138-145.	1.7	19
113	Use of aliskiren in a "real-life" model of hypertension management. <i>Journal of Hypertension</i> , 2012, 30, 194-203.	0.5	19
114	Direct Renin Inhibition. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2011, 18, 93-105.	2.2	18
115	Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic. <i>Vascular Health and Risk Management</i> , 2012, 8, 371.	2.3	18
116	Reducing Cardiovascular and Cancer Risk: How to Address Global Primary Prevention in Clinical Practice. <i>Clinical Cardiology</i> , 2015, 38, 387-394.	1.8	18
117	Tortuosity, Recurrent Segments, and Bridging of the Epicardial Coronary Arteries in Patients With the Takotsubo Syndrome. <i>American Journal of Cardiology</i> , 2017, 119, 243-248.	1.6	18
118	Prognostic Implications of Defibrillation Threshold Testing in Patients With Hypertrophic Cardiomyopathy. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 103-108.	1.7	18
119	Executive Summary of the 2018 Joint Consensus Document on Cardiovascular Disease Prevention in Italy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018, 25, 327-341.	2.2	18
120	Serum Uric Acid and Kidney Disease Measures Independently Predict Cardiovascular and Total Mortality: The Uric Acid Right for Heart Health (URRAH) Project. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 713652.	2.4	18
121	Hypertension as an Underlying Factor in Heart Failure With Preserved Ejection Fraction. <i>Journal of Clinical Hypertension</i> , 2010, 12, 277-283.	2.0	17
122	Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients. <i>Journal of Hypertension</i> , 2012, 30, 1468-1477.	0.5	17
123	Prevalence and Control of Hypertension in Different Macro-Areas in Italy: Analysis of a Large Database by the General Practice. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2016, 23, 387-393.	2.2	17
124	Updated Recommendations on Cardiovascular Prevention in 2022: An Executive Document of the Italian Society of Cardiovascular Prevention. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 91-102.	2.2	17
125	The REassessment of Antihypertensive Chronic Therapy (REACT) Study. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2004, 11, 175-185.	2.2	16
126	Microalbuminuria independently correlates to cardiovascular comorbidity burden in patients with hypertension. <i>Clinical Research in Cardiology</i> , 2012, 101, 761-766.	3.3	16



#	ARTICLE	IF	CITATIONS
127	Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan. <i>Advances in Therapy</i> , 2019, 36, 278-297.	2.9	16
128	Prognostic relevance of GRACE risk score in Takotsubo syndrome. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 721-728.	1.0	16
129	Italian Society of Arterial Hypertension (SIIA) Position Paper on the Role of Renal Denervation in the Management of the Difficult-to-Treat Hypertensive Patient. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 109-117.	2.2	16
130	Inhibition of the renin-angiotensin-aldosterone system. <i>Journal of Hypertension</i> , 2012, 30, 647-654.	0.5	15
131	Adding markers of organ damage to risk score models improves cardiovascular risk assessment: Prospective analysis of a large cohort of adult outpatients. <i>International Journal of Cardiology</i> , 2017, 248, 342-348.	1.7	15
132	Long-Term Left Ventricular Remodeling of Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2018, 122, 1924-1931.	1.6	15
133	Blood Pressure Targets Achievement According to 2018 ESC/ESH Guidelines in Three European Excellence Centers for Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 51-59.	2.2	15
134	Risk Stratification in Hypertrophic Cardiomyopathy. Insights from Genetic Analysis and Cardiopulmonary Exercise Testing. <i>Journal of Clinical Medicine</i> , 2020, 9, 1636.	2.4	15
135	Blockade of the neurohormonal systems in heart failure with preserved ejection fraction: A contemporary meta-analysis. <i>International Journal of Cardiology</i> , 2020, 316, 172-179.	1.7	15
136	Coronavirus disease 2019 in patients with cardiovascular disease: clinical features and implications on cardiac biomarkers assessment. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 832-839.	1.5	15
137	Trehalose, a natural disaccharide, reduces stroke occurrence in the stroke-prone spontaneously hypertensive rat. <i>Pharmacological Research</i> , 2021, 173, 105875.	7.1	15
138	Serum uric acid levels threshold for mortality in diabetic individuals: The URic acid Right for heArt Health (URRAH) project. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1245-1252.	2.6	15
139	Treatment priorities and current prescribing patterns in hypertension: results of GRASP, an international physician survey. <i>Current Medical Research and Opinion</i> , 2004, 20, 1151-1160.	1.9	14
140	Redefining Blood Pressure Targets in High-Risk Patients?: Lessons From Coronary Endpoints in Recent Randomized Clinical Trials. <i>American Journal of Hypertension</i> , 2011, 24, 1060-1068.	2.0	14
141	Novel $\alpha$ -galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease. <i>Gene</i> , 2014, 535, 365-369.	2.2	14
142	Cardiovascular disease in women with HIV-1 infection. <i>International Journal of Cardiology</i> , 2017, 241, 50-56.	1.7	14
143	Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 463-472.	2.2	14
144	Fifteen years of LIFE (Losartan Intervention for Endpoint Reduction in Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 Td (Hypertension, 2018, 20, 1153-1159.	2.0	14

#	ARTICLE	IF	CITATIONS
145	Implications of Guidelines for Hypertension Management in Europe. <i>Circulation Research</i> , 2019, 124, 972-974.	4.5	14
146	Reclassification of Hypertensive Outpatients According to New US Guidelines on High Blood Pressure. <i>American Journal of Hypertension</i> , 2019, 32, 77-87.	2.0	14
147	Recommendations for Cardiovascular Prevention During the Sars-Cov-2 Pandemic: An Executive Document by the Board of the Italian Society of Cardiovascular Prevention. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 373-377.	2.2	14
148	Longitudinal changes of left and right cardiac structure and function in patients with end-stage renal disease on replacement therapy. <i>European Journal of Internal Medicine</i> , 2020, 78, 95-100.	2.2	14
149	Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum. <i>Frontiers in Physiology</i> , 2021, 12, 652163.	2.8	14
150	Global Cardiovascular Risk Assessment in Different Clinical Settings. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2009, 16, 55-63.	2.2	13
151	Use of Electronic Support for Implementing Global Cardiovascular Risk Management. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2010, 17, 37-47.	2.2	13
152	New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil. <i>Integrated Blood Pressure Control</i> , 2012, 5, 19.	1.2	13
153	A Novel Electrocardiographic Tâ€Wave Measurement (Tpâ€Te Interval) as a Predictor of Heart Abnormalities in Hypertension: A New Opportunity for Firstâ€Line Electrocardiographic Evaluation. <i>Journal of Clinical Hypertension</i> , 2015, 17, 441-449.	2.0	13
154	Novel Insights Into the Mechanisms Regulating Pro-Atrial Natriuretic Peptide Cleavage in the Heart and Blood Pressure Regulation. <i>Circulation Research</i> , 2016, 118, 196-198.	4.5	13
155	Favourable impact of statin use on diastolic blood pressure levels. <i>Journal of Hypertension</i> , 2017, 35, 2086-2094.	0.5	13
156	New approach to blood pressure control: Triple combination pill. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 72-77.	4.9	13
157	Reduction in estimated stroke risk associated with practice-based stroke-risk assessment and awareness in a large, representative population of hypertensive patients: results from the ForLife study in Italy. <i>Journal of Hypertension</i> , 2007, 25, 2390-2397.	0.5	12
158	Long-Term Outcome of Acute Coronary Syndromes in Young Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 77-84.	2.2	12
159	Management of arterial hypertension with angiotensin receptor blockers: Current evidence and the role of olmesartan. <i>Cardiovascular Therapeutics</i> , 2018, 36, e12471.	2.5	12
160	The T2238C Human Atrial Natriuretic Peptide Molecular Variant and the Risk of Cardiovascular Diseases. <i>International Journal of Molecular Sciences</i> , 2018, 19, 540.	4.1	12
161	Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 399-404.	2.2	12
162	Frequency and Prognosis of Treated Hypertensive Patients According to Prior and New Blood Pressure Goals. <i>Hypertension</i> , 2019, 74, 130-136.	2.7	12

#	ARTICLE	IF	CITATIONS
163	Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: A new challenge overcome?. <i>International Journal of Cardiology</i> , 2020, 321, 150-154.	1.7	12
164	Prevalence of metabolic syndrome in the clinical practice of general medicine in Italy. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 271-9.	1.7	12
165	Relationship Between Cardiorespiratory Fitness, Baseline Blood Pressure and Hypertensive Response to Exercise in the Ferrari Corporate Population. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 29, 81.	2.2	12
166	Integrated cardiovascular risk management for the future: lessons learned from the ASCOT trial. <i>Ageing Clinical and Experimental Research</i> , 2005, 17, 46-53.	2.9	12
167	Impact of dialysis modality on the appropriateness of left ventricular mass in patients with end-stage renal disease. <i>International Journal of Cardiology</i> , 2011, 149, 250-252.	1.7	11
168	Impact of Diabetes Mellitus on the Clinical Management of Global Cardiovascular Risk: Analysis of the Results of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitization (EFFECTUS) Educational Program. <i>Clinical Cardiology</i> , 2011, 34, 560-566.	1.8	11
169	QT spatial dispersion and sudden cardiac death in hypertrophic cardiomyopathy: Time for reappraisal. <i>Journal of Cardiology</i> , 2017, 70, 310-315.	1.9	11
170	Conventional and new electrocardiographic criteria for hypertension-mediated cardiac organ damage: A narrative review. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1863-1871.	2.0	11
171	Molecular and clinical implications of natriuretic peptides in aortic valve stenosis. <i>Journal of Molecular and Cellular Cardiology</i> , 2019, 129, 266-271.	1.9	11
172	The neglected issue of cardiac amyloidosis in trials on heart failure with preserved ejection fraction in the elderly. <i>European Journal of Heart Failure</i> , 2020, 22, 1740-1741.	7.1	11
173	Regulation of Aldosterone Biosynthesis by Adrenal Renin Is Mediated Through AT <sub>1</sub> Receptors in Renin Transgenic Rats. <i>Circulation Research</i> , 1995, 77, 73-79.	4.5	11
174	Understanding and treating hypertension in diabetic populations. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 353-63.	1.7	11
175	Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice. <i>International Journal of Cardiology</i> , 2022, 349, 134-137.	1.7	11
176	Antihypertensive Efficacy and Safety of Olmesartan Medoxomil and Ramipril in Elderly Mild to Moderate Essential Hypertensive Patients With or Without Metabolic Syndrome. <i>Drugs and Aging</i> , 2012, 29, 981-992.	2.7	10
177	Olmesartan in the Treatment of Hypertension in Elderly Patients: a Review of the Primary Evidence. <i>Drugs and Aging</i> , 2013, 30, 987-998.	2.7	10
178	The C2238/±ANP Variant Is a Negative Modulator of Both Viability and Function of Coronary Artery Smooth Muscle Cells. <i>PLoS ONE</i> , 2014, 9, e113108.	2.5	10
179	Natriuretic peptides and volume handling in heart failure: the paradigm of a new treatment. <i>European Journal of Heart Failure</i> , 2016, 18, 442-444.	7.1	10
180	NT-proANP and NT-proBNP circulating levels as predictors of cardiovascular outcome following coronary stent implantation. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 162-168.	0.8	10

#	ARTICLE	IF	CITATIONS
181	Safety and efficacy of anti-tachycardia pacing in patients with hypertrophic cardiomyopathy implanted with an ICD. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 610-616.	1.2	10
182	Hypertension in the elderly: which are the blood pressure threshold values?. <i>European Heart Journal Supplements</i> , 2019, 21, B105-B106.	0.1	10
183	Clinical characteristics of patients with takotsubo syndrome recurrence: An observational study with long-term follow-up. <i>International Journal of Cardiology</i> , 2021, 329, 23-27.	1.7	10
184	Preexisting Oral Anticoagulant Therapy Ameliorates Prognosis in Hospitalized COVID-19 Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 633878.	2.4	10
185	Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology. <i>European Journal of Internal Medicine</i> , 2022, 102, 8-16.	2.2	10
186	Antihypertensive therapy and cerebrovascular protection. <i>Current Opinion in Nephrology and Hypertension</i> , 2006, 15, 498-504.	2.0	9
187	Cardiovascular Prevention in Subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2010, 17, 73-102.	2.2	9
188	The cardiovascular continuum refined: A hypothesis. <i>Blood Pressure</i> , 2010, 19, 273-277.	1.5	9
189	End-Organ Protection in Patients with Hypertension. <i>Drugs</i> , 2011, 71, 1003-1017.	10.9	9
190	Plasma Renin and Cardiovascular Risk: What Is the Evidence for an Association?. <i>Cardiology</i> , 2013, 125, 50-59.	1.4	9
191	Open-Label Study Assessing the Long-term Efficacy and Safety of Triple Olmesartan/Amlodipine/Hydrochlorothiazide Combination Therapy for Hypertension. <i>Advances in Therapy</i> , 2014, 31, 561-574.	2.9	9
192	Transfemoral approach with systematic use of FemoSeal <sup>®</sup> closure device compared to transradial approach in primary angioplasty. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 849-854.	1.7	9
193	2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 313-329.	2.2	9
194	Achievement of multiple therapeutic targets for cardiovascular disease prevention: Retrospective analysis of real practice in Italy. <i>Clinical Cardiology</i> , 2018, 41, 788-796.	1.8	9
195	Legacy Effect in the Treatment of Hypertension: Persistent Cardiovascular Protection after Conclusion of Randomized Clinical Trials in Hypertension. <i>Current Hypertension Reports</i> , 2019, 21, 85.	3.5	9
196	A systematic review on focal takotsubo syndrome: a not-so-small matter. <i>Heart Failure Reviews</i> , 2022, 27, 271-280.	3.9	9
197	High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1501-1509.	1.8	9
198	Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike?. <i>European Heart Journal</i> , 2021, 42, 3753-3755.	2.2	9

#	ARTICLE	IF	CITATIONS
199	Novel ANP (Atrial Natriuretic Peptide)-Based Therapy for Hypertension: The Promising Role of a Disease Mechanism Targeted Approach. <i>Hypertension</i> , 2021, 78, 1868-1870.	2.7	9
200	World Hypertension Day 2021 in Italy: Results of a Nationwide Survey. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 353-359.	2.2	9
201	Hypertension and Heart Failure: Role of Neurohormonal Mechanisms. <i>Clinical and Experimental Hypertension</i> , 2004, 26, 603-610.	1.3	8
202	Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1061-1072.	1.5	8
203	Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 331-339.	2.2	8
204	Therapeutic Approach to Hypertension Urgencies and Emergencies During Acute Coronary Syndrome. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018, 25, 253-259.	2.2	8
205	Blood Pressure Target Achievement Under Monotherapy: A Real-Life Appraisal. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 587-596.	2.2	8
206	The emotional and social burden of heart failure: integrating physiciansâ€™™, patientsâ€™™, and caregiversâ€™™ perspectives through narrative medicine. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 522.	1.7	8
207	A Contemporary View of Natriuretic Peptides in the SARS-CoV-2 Era. <i>Frontiers in Physiology</i> , 2021, 12, 643721.	2.8	8
208	Novel Imaging and Genetic Risk Markers in Takotsubo Syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 703418.	2.4	8
209	Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test. <i>Journal of Cardiac Failure</i> , 2020, 26, 932-943.	1.7	8
210	Antihypertensive drugs and the risk of cancer: a critical review of available evidence and perspective. <i>Journal of Hypertension</i> , 2020, 38, 1005-1015.	0.5	8
211	Recent Warnings about Antihypertensive Drugs and Cancer Risk: Where Do They Come From?. <i>European Cardiology Review</i> , 2020, 15, e21.	2.2	8
212	Ventriculo-arterial coupling in the intensive cardiac care unit: A non-invasive prognostic parameter. <i>International Journal of Cardiology</i> , 2022, 348, 85-89.	1.7	8
213	Long-Term Tolerability and Efficacy of the Fixed Combination of Manipine and Delapril in Patients with Essential Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2003, 10, 81-86.	2.2	7
214	Angiotensin II-receptor antagonist in the treatment of hypertension. <i>Current Hypertension Reports</i> , 2005, 7, 287-293.	3.5	7
215	An Analysis of the Management of Cardiovascular Risk Factors in Routine Clinical Practice in Italy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2011, 18, 19-30.	2.2	7
216	Angiotensin Receptor Antagonists to Prevent Sudden Death in Heart Failure: Does the Dose Matter?. <i>ISRN Cardiology</i> , 2014, 2014, 1-7.	1.6	7

#	ARTICLE	IF	CITATIONS
217	Impact of Hypertension on Global Cardiovascular Risk Stratification: Analysis of a Large Cohort of Outpatient Population in Italy. <i>Clinical Cardiology</i> , 2015, 38, 39-47.	1.8	7
218	Attitudes and preferences for the clinical management of patients with hypertension and hypertension with chronic obstructive pulmonary disease in Italy: main results of a survey questionnaire. <i>Internal and Emergency Medicine</i> , 2015, 10, 943-954.	2.0	7
219	Data on the lipoprotein (a), coronary atherosclerotic burden and vulnerable plaque phenotype in angiographic obstructive coronary artery disease. <i>Data in Brief</i> , 2016, 7, 1409-1412.	1.0	7
220	Hypertensive crisis management in the emergency room. <i>Journal of Hypertension</i> , 2020, 38, 33-34.	0.5	7
221	Natriuretic Peptides, Cognitive Impairment and Dementia: An Intriguing Pathogenic Link with Implications in Hypertension. <i>Journal of Clinical Medicine</i> , 2020, 9, 2265.	2.4	7
222	Functional Role of Natriuretic Peptides in Risk Assessment and Prognosis of Patients with Mitral Regurgitation. <i>Journal of Clinical Medicine</i> , 2020, 9, 1348.	2.4	7
223	Early echocardiographic modifications after flow reduction by proximal radial artery ligation in patients with high-output heart failure due to high-flow forearm arteriovenous fistula. <i>Journal of Vascular Access</i> , 2020, 21, 753-759.	0.9	7
224	Usefulness of the corporate wellness projects in primary prevention at the population level: a study on the prevalence, awareness, and control of hypertension in the Ferrari company. <i>Journal of Human Hypertension</i> , 2021, , .	2.2	7
225	The key role of blood pressure lowering in cardiovascular prevention irrespective of baseline blood pressure and risk profile. <i>European Heart Journal</i> , 2021, 42, 2814-2815.	2.2	7
226	Cardiovascular Risk Profile in 1477513 Patients with Essential Hypertension Followed by Italian Specialist Physicians. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2004, 11, 165-173.	2.2	6
227	Arterial Stiffness and Cognitive Impairment in the Elderly. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 33-37.	2.2	6
228	Chronic Kidney Disease in the Hypertensive Patient. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2011, 18, 31-36.	2.2	6
229	2010 Position Paper of the Italian Society of Hypertension (SIIA). <i>High Blood Pressure and Cardiovascular Prevention</i> , 2011, 18, 37-40.	2.2	6
230	Integrated Preclinical Cardiovascular Prevention: A New Paradigm to Face Growing Challenges of Cardiovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 163-170.	2.2	6
231	Hypertension Across the Atlantic: A Sprint or a Marathon?. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 99-102.	2.2	6
232	Effects of different statin types and dosages on systolic/diastolic blood pressure: Retrospective analysis of 24-hour ambulatory blood pressure database. <i>Journal of Clinical Hypertension</i> , 2018, 20, 967-975.	2.0	6
233	Tales in Cardiology. <i>European Heart Journal</i> , 2019, 40, 800-802.	2.2	6
234	Atrial natriuretic peptide predicts disease progression and digital ulcers development in systemic sclerosis patients. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 771-779.	1.5	6

#	ARTICLE	IF	CITATIONS
235	24-Hour ambulatory blood pressure levels and control in a large cohort of adult outpatients with different classes of obesity. <i>Journal of Human Hypertension</i> , 2019, 33, 298-307.	2.2	6
236	COVID-19 and the Forgotten Majority. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 339-339.	2.2	6
237	The EMPEROR-Preserved study: end of the search for the "Phoenix" or beginning of a new season for trials in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2021, 42, 4621-4623.	2.2	6
238	SARS-CoV-2 infection markedly increases long-term cardiovascular risk. <i>European Heart Journal</i> , 2022, 43, 1899-1900.	2.2	6
239	Hypertension therapy: Mixing, matching, and meeting targets. <i>Advances in Therapy</i> , 2004, 21, 107-122.	2.9	5
240	Angiotensin II: An amplifier of cardiovascular risk. <i>Current Hypertension Reports</i> , 2004, 6, 247-248.	3.5	5
241	Clinical Management of Coronary Heart Disease in Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2013, 20, 129-134.	2.2	5
242	Î± <sub>2A</sub> -Adrenergic Receptor Polymorphism Potentiates Platelet Reactivity in Patients With Stable Coronary Artery Disease Carrying the Cytochrome P450 2C19*2 Genetic Variant. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1314-1319.	2.4	5
243	Olmesartan vs ramipril in the treatment of hypertension and associated clinical conditions in the elderly: a reanalysis of two large double blind, randomized studies at the light of the most recent blood pressure targets recommended by guidelines. <i>Clinical Interventions in Aging</i> , 2015, 10, 1575.	2.9	5
244	Shooting vascular oxidative stress: new hopes for stroke patients?: Figure 1. <i>European Heart Journal</i> , 2015, 36, 1573-1575.	2.2	5
245	New Opportunities for Monitoring Blood Pressure Control and Awareness in the Population: Insights from 12-Year Editions of the World Hypertension Day. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2016, 23, 333-335.	2.2	5
246	Hypertension in Patients with Heart Failure with Reduced Ejection Fraction. <i>Current Cardiology Reports</i> , 2016, 18, 127.	2.9	5
247	Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 243-253.	2.2	5
248	Increased arterial stiffness and haemorrhagic transformation in ischaemic stroke after thrombolysis: A new marker of risk for cerebrovascular events and complications. <i>International Journal of Cardiology</i> , 2017, 243, 471-472.	1.7	5
249	Attitudes and preferences for the clinical management of hypertension and hypertension-related cerebrovascular disease in the general practice: results of the Italian hypertension and brain survey. <i>Clinical Hypertension</i> , 2017, 23, 10.	2.0	5
250	Inflammatory residual risk: An emerging target to reduce cardiovascular disease?. <i>Clinical Cardiology</i> , 2018, 41, 437-439.	1.8	5
251	Antihypertensive drugs and the risks of cancer: More fakes than facts. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1323-1326.	1.8	5
252	Effect of Pycnogenol on Blood Pressure: Findings From a PRISMA Compliant Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled, Clinical Studies. <i>Angiology</i> , 2020, 71, 217-225.	1.8	5

#	ARTICLE	IF	CITATIONS
253	Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists. <i>Cardiovascular Research</i> , 2021, 117, 1992-1994.	3.8	5
254	Prognostic implications of nonsustained ventricular tachycardia morphology in high-risk patients with hypertrophic cardiomyopathy. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 2093-2098.	1.7	5
255	Circulating NT-proANP level is a predictor of mortality for systemic sclerosis: a retrospective study of an Italian cohort. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 661-666.	3.0	5
256	Cardiovascular Risk Management in Clinical Practice. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008, 15, 9-16.	2.2	4
257	A New Option for Therapeutic Management of Patients with Cardiovascular Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008, 15, 47-51.	2.2	4
258	2008 White Paper for Implementing Strategies and Interventions for Cardiovascular Prevention in Italy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008, 15, 63-73.	2.2	4
259	Cardiovascular Risk in Hypertension – Can We Ask for More?. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008, 15, 255-268.	2.2	4
260	NT-proANP/ANP is a Determinant of Vascular Damage in Humans. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2010, 17, 117-120.	2.2	4
261	RyR2 Common Gene Variant G1886S and the Risk of Ventricular Arrhythmias in ICD Patients with Heart Failure. <i>Journal of Cardiovascular Electrophysiology</i> , 2015, 26, 656-661.	1.7	4
262	BNP level and post-transcatheter aortic valve replacement outcome: an intriguing J-shaped relationship. <i>European Heart Journal</i> , 2020, 41, 970-972.	2.2	4
263	May Measurement Month 2018: an analysis of blood pressure screening results from Italy. <i>European Heart Journal Supplements</i> , 2020, 22, H70-H73.	0.1	4
264	Atrial fibrillation and ischaemic heart disease: should we use acetylsalicylic acid beside anticoagulants?. <i>European Heart Journal Supplements</i> , 2020, 22, L166-L169.	0.1	4
265	Sacubitril/Valsartan: Potential Impact of ARNi – Beyond the Wall of ACE2 on Treatment and Prognosis of Heart Failure Patients With Coronavirus Disease-19. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 616564.	2.4	4
266	The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending. <i>European Heart Journal</i> , 2021, 42, 1458-1459.	2.2	4
267	May Measurement Month 2019: an analysis of blood pressure screening results from Italy. <i>European Heart Journal Supplements</i> , 2021, 23, B77-B81.	0.1	4
268	The increased mortality of STEMI patients without risk factors supports the need for evidence-based pharmacotherapy irrespective of perceived low risk. <i>European Heart Journal</i> , 2021, 42, 2329-2330.	2.2	4
269	Long-term management of Takotsubo syndrome: a not-so-benign condition. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, 597.	1.4	4
270	The REDUCE-IT verdict on eicosapentaenoic acid and cardiovascular outcome challenged with STRENGTH. <i>European Heart Journal</i> , 2021, 42, 370-371.	2.2	4



#	ARTICLE	IF	CITATIONS
271	Aldosterone receptor antagonism in patients with diabetes and chronic kidney disease: new promises and old problems. <i>European Heart Journal</i> , 2021, 42, 14-15.	2.2	4
272	Current applications and limitations of European guidelines on blood pressure measurement: implications for clinical practice. <i>Internal and Emergency Medicine</i> , 2022, 17, 645-654.	2.0	4
273	PARADISE-MI suggests a limited role of intensified neuro-hormonal inhibition in the management of acute myocardial infarction with reduced ejection fraction. <i>European Heart Journal</i> , 2022, 43, 559-560.	2.2	4
274	New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies. <i>Medical Sciences (Basel)</i> , 2021, 10, 1000000.	2.9	4
275	Protocol for an Observational Blood Pressure Study. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2004, 11, 11-14.	2.2	3
276	Prevalence of "Borderline" Values of Cardiovascular Risk Factors in the Clinical Practice of General Medicine in Italy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2011, 18, 43-51.	2.2	3
277	An easy and reproducible parameter for the assessment of the pressure gradient in patients with aortic stenosis disease: A magnetic resonance study. <i>Journal of Cardiology</i> , 2015, 65, 369-376.	1.9	3
278	Angiotensin II-Linked Hypothesis to Understand the Advantage of the Coevolution of Hypertension and Malaria. <i>Circulation Research</i> , 2016, 119, 1046-1048.	4.5	3
279	Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 255-263.	2.2	3
280	Novel blood pressure targets in patients with high-normal levels and grade 1 hypertension: Room for monotherapy?. <i>International Journal of Cardiology</i> , 2019, 291, 105-111.	1.7	3
281	Immigration Emergency in Italy: The Impact of Socioeconomic Status on Blood Pressure Levels and Control. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 467-473.	2.2	3
282	An evolutionary rebus. <i>Journal of Hypertension</i> , 2019, 37, 1344-1346.	0.5	3
283	Effects of dual inhibition of renin-angiotensin-aldosterone system on cardiovascular and renal outcomes: balancing the risks and the benefits. <i>Internal and Emergency Medicine</i> , 2020, 15, 373-379.	2.0	3
284	Risk stratifying asymptomatic left ventricular systolic dysfunction in the community: beyond left ventricular ejection fraction. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 1405-1411.	1.2	3
285	OUP accepted manuscript. <i>European Heart Journal</i> , 2021, 42, 4789-4790.	2.2	3
286	Prevalence and clinical characteristics of isolated systolic hypertension in young: analysis of 24h ambulatory blood pressure monitoring database. <i>Journal of Human Hypertension</i> , 2022, 36, 40-50.	2.2	3
287	A SPRINT towards tighter control of blood pressure in hypertension. <i>European Heart Journal</i> , 2021, 42, 3042-3043.	2.2	3
288	Global Cardiovascular Risk Management in Primary Prevention. <i>Current Vascular Pharmacology</i> , 2012, 10, 709-711.	1.7	3

#	ARTICLE	IF	CITATIONS
289	Targeting Cyclic Guanylate Monophosphate in Resistant Hypertension and Heart Failure: Are Sacubitril/Valsartan and Vericiguat Synergistic and Effective in Both Conditions?. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 541-545.	2.2	3
290	Reduction of High Cholesterol Levels by a Preferably Fixed-Combination Strategy as the First Step in the Treatment of Hypertensive Patients with Hypercholesterolemia and High/Very High Cardiovascular Risk: A Consensus Document by the Italian Society of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 105-113.	2.2	3
291	Antithrombotic Strategies in Patients with Atrial Fibrillation and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Journal of Clinical Medicine, 2022, 11, 512.	2.4	3
292	Myocarditis after BNT162b2 mRNA SARS-CoV-2 vaccine: low incidence and mild severity. European Heart Journal, 2022, , .	2.2	3
293	Therapeutic implications of recent megatrials in hypertension: in favor of new drugs. Journal of Nephrology, 2007, 20 Suppl 12, S12-8.	2.0	3
294	Extemporaneous combination therapy with nebivolol/zofenopril in hypertensive patients: usage in Italy. Current Medical Research and Opinion, 2022, 38, 1673-1681.	1.9	3
295	Evidence-Based Indications in Hypertensive Patients. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 1-7.	2.2	2
296	Treating Hypertension with Angiotensin II Receptor Blockers. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 9-15.	2.2	2
297	Similarities and Differences in Hypertension Guidelines. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 63-66.	2.2	2
298	High Blood Pressure & Cardiovascular Prevention. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 1-3.	2.2	2
299	Effects of Olmesartan on Endothelial Function. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 221-227.	2.2	2
300	TRANSCEND Aftermath. High Blood Pressure and Cardiovascular Prevention, 2009, 16, 1-6.	2.2	2
301	Cardiovascular Prevention: The Role of Second Generation of Nutraceuticals. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 155-157.	2.2	2
302	Tpâ€Te interval predicts heart rate reduction after fingolimod administration in patients with multiple sclerosis. International Journal of Cardiology, 2016, 221, 881-885.	1.7	2
303	Autonomic cardiovascular control and cardiac arrhythmia in two pregnant women with hypertrophic cardiomyopathy: Insights from ICD monitoring. Revista Portuguesa De Cardiologia, 2018, 37, 351.e1-351.e4.	0.5	2
304	The â€œhidden side of the moonâ€ in hypertension: When and why is dangerous low diastolic blood pressure?. International Journal of Cardiology, 2019, 276, 268-270.	1.7	2
305	Genes and hypertension: stepping into the secret through the arterial wall. European Heart Journal, 2020, 41, 3323-3324.	2.2	2
306	Systolic blood pressure target less than 120â€ŠmmHg: the â€Chariot Allegoryâ€™ in hypertension?. Journal of Hypertension, 2020, 38, 1462-1463.	0.5	2

#	ARTICLE	IF	CITATIONS
307	Decline in blood pressure control trends in the US: a real step back: Comment on National Health and Nutrition Examination Survey (NHANES) data. <i>European Heart Journal</i> , 2020, 41, 3986-3987.	2.2	2
308	Epidemiological Impact and Clinical Consequences of Masked Hypertension: A Narrative Review. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 195-201.	2.2	2
309	A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19. <i>European Heart Journal</i> , 2021, 42, 1061-1062.	2.2	2
310	Role of induced pluripotent stem cells in diagnostic cardiology. <i>World Journal of Stem Cells</i> , 2021, 13, 331-341.	2.8	2
311	Glycoprotein IIb/IIIa Inhibitors May Modulate the Clinical Benefit of Radial Access as Compared to Femoral Access in Primary Percutaneous Coronary Intervention: A Meta-Regression and Meta-Analysis of Randomized Trials. <i>Journal of Interventional Cardiology</i> , 2021, 2021, 1-9.	1.2	2
312	Unhealthy lifestyles mediate only a small proportion of the socioeconomic inequalitiesâ€™ impact on cardiovascular outcomes in US and UK adults: a call for action for social cardiology. <i>European Heart Journal</i> , 2021, 42, 2420-2421.	2.2	2
313	Hypertension Management and Control in Italy: A Real-World Survey in Elderly Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 425-426.	2.2	2
314	The cardiovascular benefits of statins outweigh adverse effects in primary prevention: results of a large systematic review and meta-analysis. <i>European Heart Journal</i> , 2021, 42, 4518-4519.	2.2	2
315	Are post-hoc analyses on subgroups sufficient to support new treatment algorithms of heart failure? The case of SGLT2 inhibitors associated with sacubitril/valsartan. <i>Cardiology</i> , 2021, , .	1.4	2
316	Effect of direct renin inhibition on vascular function after long-term treatment with aliskiren in hypertensive and diabetic patients. <i>Journal of Hypertension</i> , 2021, 39, 169-180.	0.5	2
317	Implantable recorders and systematic atrial fibrillation detection do not outperform standard of care in stroke prevention in the LOOP study. <i>European Heart Journal</i> , 2022, 43, 261-262.	2.2	2
318	Unloading left heart with a shunt device shows no benefits in heart failure with preserved ejection fraction but supports the importance of phenotyping patients in clinical trials. <i>European Heart Journal</i> , 2022, 43, 1700-1701.	2.2	2
319	The REACT Study. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2004, 11, 61-63.	2.2	1
320	A Novel Molecule of the Angiotensin II Receptor Blocker Class. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2005, 12, 79-89.	2.2	1
321	Natriuretic Peptides. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2005, 12, 215-223.	2.2	1
322	Upcoming Challenges for Training in Cardiology. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 201-206.	2.2	1
323	Vascular Senescence at the Crossroad between Oxidative Stress and Nitric Oxide Pathways. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008, 15, 17-22.	2.2	1
324	A New Option for Therapeutic Management of Patients with Cerebrovascular Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008, 15, 105-107.	2.2	1

#	ARTICLE	IF	CITATIONS
325	An atypical clinical presentation of renovascular hypertension. <i>International Journal of Cardiology</i> , 2014, 177, e107-e110.	1.7	1
326	Erythropoiesis-stimulating agents in heart failure: leave it or re-take it?. <i>European Journal of Heart Failure</i> , 2015, 17, 1089-1090.	7.1	1
327	Synergistic effects of cardiac resynchronization therapy and drug up-titration in heart failure: is this enough?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 189-190.	3.0	1
328	The Age of Nutraceuticals: Exploring New Therapeutic Targets. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2016, 23, 337-339.	2.2	1
329	Time Trend Analysis of Hypertension Prevalence, Awareness, Treatment and Control in Italy: Novel Insights from Recent National Surveys in the General Population. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 103-105.	2.2	1
330	Patient at intermediate cardiovascular risk. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, e130-e132.	1.5	1
331	Calcium Channel Blockers for the Clinical Management of Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018, 25, 1-3.	2.2	1
332	Measuring Central or Peripheral Blood Pressure Levels? That is the Question in the Modern Clinical Practice of Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018, 25, 415-416.	2.2	1
333	Lifestyle and cardiovascular disease: Barefooting through the guidelines. <i>International Journal of Cardiology</i> , 2018, 263, 156-157.	1.7	1
334	Search of multiple markers of organ damage for better cardiovascular risk stratification in hypertension: Role of "SHATS" syndrome in the clinical practice. <i>International Journal of Cardiology</i> , 2018, 263, 154-155.	1.7	1
335	Predictive Role of High Blood Pressure for the Incidence of Metabolic Syndrome. <i>Cardiology</i> , 2019, 142, 232-234.	1.4	1
336	Xanthine oxidase inhibitors in elderly patients with heart failure: useful or useless?. <i>Internal and Emergency Medicine</i> , 2019, 14, 903-905.	2.0	1
337	Electrocardiographic changes in focal takotsubo syndrome. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 783-786.	1.5	1
338	Aspirin in primary prevention. <i>Journal of Hypertension</i> , 2019, 37, 2298-2299.	0.5	1
339	Excess of dyslipidemia in low income countries: The case of Colombia in the PURE study. <i>International Journal of Cardiology</i> , 2019, 290, 152-153.	1.7	1
340	T2238C atrial natriuretic peptide gene variant and cardiovascular events in patients with atrial fibrillation: A substudy from the ATHERO-AF cohort. <i>International Journal of Cardiology</i> , 2021, 322, 245-249.	1.7	1
341	Real-life appraisal on blood pressure targets achievement in adult outpatients at high cardiovascular risk. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 472-480.	2.6	1
342	The UrgeRe (Urgenze Ipertensive: Un Progetto Educazionale Fondato Sulla Vita Reale, Hypertensive) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 2021, 28, 151-157.	2.2	1

#	ARTICLE	IF	CITATIONS
343	Cryoblation as first-line treatment of new-onset atrial fibrillation?. European Heart Journal, 2021, 42, 1543-1544.	2.2	1
344	ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 255-262.	2.2	1
345	A "Once-and-Done"™ Approach to the Lifelong Reduction of Elevated Cholesterol. European Heart Journal, 2021, 42, 3820-3821.	2.2	1
346	Exploring RNA biomarkers in patients with acute myocarditis. European Heart Journal, 2021, 42, 3425-3426.	2.2	1
347	An inflammatory ageing clock to detect cardiovascular and other age-related diseases: a new approach to preventive medicine. European Heart Journal, 2021, 42, 4296-4297.	2.2	1
348	Repurposing Cardio-Metabolic Drugs to Fight Covid19. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 419-423.	2.2	1
349	Follow-up, study design and outcome parameters. EuroIntervention, 2013, 9, R96-R100.	3.2	1
350	OUP accepted manuscript. European Heart Journal, 2021, 42, 4885-4886.	2.2	1
351	VANISHing the progression of cardiac abnormalities in hypertrophic cardiomyopathy with early use of valsartan?. European Heart Journal, 2022, 43, 181-182.	2.2	1
352	Age-independent benefits of blood pressure lowering: are they applicable to all patients?. European Heart Journal, 2022, 43, 448-449.	2.2	1
353	Blood pressure lowering drugs differ in their capacity to prevent type 2 diabetes. European Heart Journal, 2022, , .	2.2	1
354	Biological relevance of a proANP molecular variant in human endothelial cells. American Journal of Hypertension, 2003, 16, A67.	2.0	0
355	Treatment of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2003, 10, 7-9.	2.2	0
356	The Multicentre Atorvastatin Plaque Stabilisation (MAPS) Study. High Blood Pressure and Cardiovascular Prevention, 2003, 10, 11-18.	2.2	0
357	The New JNC VII and ESH/ISH Hypertension Recommendations. High Blood Pressure and Cardiovascular Prevention, 2003, 10, 65-67.	2.2	0
358	Evolving Pathophysiological Perspectives in Endothelial Dysfunction. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 47-53.	2.2	0
359	Hypertension Surveys. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 157-158.	2.2	0
360	Head-to-Head Intervention Trials in Hypertension. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 1-4.	2.2	0

#	ARTICLE	IF	CITATIONS
361	What Should We Expect from the Next Guidelines on Hypertension?. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 199-202.	2.2	0
362	Treatment of High-Risk Hypertensive Patients. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 13-19.	2.2	0
363	The Apelin/APJ System. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 159-162.	2.2	0
364	The Role of Arterial Stiffness in Stratifying the Overall Cardiovascular Risk. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 89-97.	2.2	0
365	The Growing Importance of Socioeconomic Aspects in Cardiovascular Disease. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 139-144.	2.2	0
366	β-Blockers and Diuretics in the Treatment of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 109-111.	2.2	0
367	The Myth of Janus. High Blood Pressure and Cardiovascular Prevention, 2009, 16, 35-37.	2.2	0
368	2009 SIPREC Consensus Document – Executive Summary. High Blood Pressure and Cardiovascular Prevention, 2010, 17, 237-247.	2.2	0
369	A Survey on Blood Pressure Levels and Hypertension Control in a Sample of the Italian General Population. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 129-135.	2.2	0
370	Renin-angiotensin system blockers increase risk of angio-oedema. Evidence-Based Medicine, 2013, 18, e52-e52.	0.6	0
371	Reducing therapeutic inertia to improve blood pressure control. Journal of Hypertension, 2014, 32, 988-989.	0.5	0
372	In Memory of Professor John H. Laragh. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 197-197.	2.2	0
373	Managing hypertension after acute coronary syndrome. Journal of Hypertension, 2015, 33, 700-701.	0.5	0
374	National Cross-Sectional Survey on Blood Pressure: A Gateway to a Better Appraisal of Hypertension in the Young. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 141-142.	2.2	0
375	What's HIV got to do with cardiovascular disease?. International Journal of Cardiology, 2018, 265, 210-211.	1.7	0
376	How much drug-induced blood pressure reduction is effective and safe in heart failure?. Journal of Hypertension, 2019, 37, 1786-1787.	0.5	0
377	How to Improve Patients' Adherence to Antihypertensive Therapy: A Simple Solution for a Big Trouble. American Journal of Hypertension, 2019, 32, 141-142.	2.0	0
378	Response to letter from Madias regarding our article – Admission heart rate and in-hospital course of patients with Takotsubo syndrome. International Journal of Cardiology, 2019, 274, 64.	1.7	0

#	ARTICLE	IF	CITATIONS
379	White-coat and masked hypertension and coronary artery disease: are they related or not?. Hypertension Research, 2020, 43, 151-152.	2.7	0
380	A Plea for Smoking-Free Policies in COVID-19 Times: Cardiovascular Prevention as an Ally in Coronavirus Containment. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 325-326.	2.2	0
381	Vulnerable non-culprit coronary plaques: are they worth treating?. European Heart Journal, 2021, 42, 2233-2234.	2.2	0
382	Glycaemic index: an emergent global silent killer for the heart. European Heart Journal, 2021, 42, 2727-2728.	2.2	0
383	Reply to the letter "Takotsubo syndrome: Any more covariates of its recurrence?". International Journal of Cardiology, 2021, 333, 54.	1.7	0
384	Worsening of risk factor control in US diabetic patients: a call to action. European Heart Journal, 2021, 42, 3120-3121.	2.2	0
385	A newly designed glucagon-like peptide-1 receptor agonist reduces cardiovascular and renal events in high-risk type 2 diabetes. European Heart Journal, 2021, 42, 3902-3903.	2.2	0
386	Computed tomography coronary angiography in acute chest pain: an excellent diagnostic tool with poor added value on clinical outcomes. European Heart Journal, 2022, 43, 103-104.	2.2	0
387	Another STEP towards tighter control of blood pressure in the elderly. European Heart Journal, 2021, 42, 4715-4716.	2.2	0
388	Abstract MP10: Early Functional and Structural Alterations of Resistance Arteries in Mice Treated with an Inhibitor of the Vascular Endothelial Growth Factor Receptor. Hypertension, 2014, 64, .	2.7	0
389	Anaemia and heart failure: is there still a role for erythropoiesis-stimulating agents?. Turk Kardiyoloji Dernegi Arsivi, 2017, 45, 217-218.	0.5	0
390	Drugs may worsen blood pressure control: focus on the underestimated role of non-steroidal anti-inflammatory drugs. European Heart Journal, 2022, , .	2.2	0
391	OUP accepted manuscript. European Heart Journal, 2022, , .	2.2	0
392	494 Glycoprotein IIB/IIIa inhibitors may modulate the clinical benefit of radial access as compared to femoral access in primary percutaneous coronary intervention: a meta-regression and a meta-analysis of randomized trials. European Heart Journal Supplements, 2021, 23, .	0.1	0
393	The DISCHARGE trial: <i>imaging</i> a new strategy for the clinical management of stable chest pain?. European Heart Journal, 2022, , .	2.2	0
394	Title is missing!. , 2020, 15, e0237297.		0
395	Title is missing!. , 2020, 15, e0237297.		0
396	Title is missing!. , 2020, 15, e0237297.		0

#	ARTICLE	IF	CITATIONS
397	Title is missing!. , 2020, 15, e0237297.		0
398	Title is missing!. , 2020, 15, e0237297.		0
399	Title is missing!. , 2020, 15, e0237297.		0
400	Detection of risk factors in childhood: a new perspective in cardiovascular prevention. European Heart Journal, 2022, , .	2.2	0
401	Treatment of mild hypertension improves pregnancy outcomes. European Heart Journal, 2022, , .	2.2	0
402	Abstract 533: MAS Receptor Activation Contributes to the Improvement of Vascular Remodeling During Chronic Angiotensin II Type 1 Receptor Blockade in Angiotensin II Type 2 Receptor Knockout Mice.. Hypertension, 2012, 60, .	2.7	0
403	Abstract 45: Reduced Vascular Remodeling and Improved Endothelial Function in Transglutaminase 2 Knock-Out Mice Treated with Angiotensin II. Hypertension, 2013, 62, .	2.7	0
404	Abstract 406: Improved Angiotensin II Type 2 Receptor Expression and Function in Transglutaminase 2 Knock-Out Mice Treated with Angiotensin II. Hypertension, 2013, 62, .	2.7	0
405	Long lasting effects of renal denervation: lights and shadows of the SPYRAL HTN-ON MED 3-year follow-up. European Heart Journal, 0, , .	2.2	0
406	The UK TAVI trial: an independent, pragmatic study extending the evidence for the treatment of symptomatic severe aortic stenosis. European Heart Journal, 0, , .	2.2	0
407	Diastolic Blood Pressure Levels and Cardiovascular Risk in Elderly Women: The Need for a Personalized Approach. American Journal of Hypertension, 0, , .	2.0	0